Skip to main content
Fig. 3 | BMC Cardiovascular Disorders

Fig. 3

From: The cost-utility of point-of-care troponin testing to diagnose acute coronary syndrome in primary care

Fig. 3

Cost-effectiveness acceptability curve of the POC troponin strategy versus current practice, for a WTP ranging from €0/QALY to €200,000/QALY. The black line represents the base case cost-effectiveness acceptability curve. The ‘non-inferiority’ and ‘-0.002 QALYs’ line represent scenarios in which POC troponin has acceptable cost-utility, and is either at least equally effective, or does not involve a decrease of ≥0.002 QALYs. QALYs = quality-adjusted life years

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us